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Background: Despite the high incidence and the economic impact of the common cold, there are still no effective
therapeutic options available. Although traditional Chinese medicine (TCM) is widely used in China to treat the
common cold, there is still a lack of high-quality clinical trials. This article sets forth the protocol for a high-quality
trial of a new TCM drug, Baoji Tablets, which is designed to treat the common cold with summer-heat and
dampness syndrome (CCSDS). The trial is evaluating both the efficacy and safety of Baoji Tablets.
Methods/design: This study is designed as a multicenter, phase II, parallel-group, double-blind, double-dummy,
randomized and placebo-controlled trial. A total of 288 patients will be recruited from four centers. The new tablets
group are administered Baoji Tablets 0.9 g and dummy Baoji Pills 3.7 g. The old pills group are administered dummy
Baoji Tablets 0.9 g and Baoji Pills 3.7 g. The placebo control group are administered dummy Baoji Tablets 0.9 g and
dummy Baoji Pills 3.7 g. All drugs are taken three times daily for 3 days. The primary outcome is the duration of all
symptoms. Secondary outcomes include the duration of primary and secondary symptoms, changes in primary and
secondary symptom scores and cumulative symptom score at day 4, as well as an evaluation of treatment efficacy.
Discussion: This is the first multicenter, double-blind, double-dummy, randomized and placebo-controlled trial
designated to treat CCSDS in an adult population from China. It will establish the basis for a scientific and objective
assessment of the efficacy and safety of Baoji Tablets for treating CCSDS, and provide evidence for a phase III clinical
trial.
Trial registration: This study is registered with the Chinese Clinical Trial Registry. The registration number is
ChiCTR-TRC-13003197.
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Randomized controlled trialBackground
The common cold is the conventional term used to de-
scribe a mild, self-limited, viral, upper respiratory tract in-
fection and it is the most prevalent disease experienced by
humans [1]. Symptoms usually include a sore or scratchy
throat, sneezing, coughing, hoarseness, runny nose, nasal
obstruction and mild general symptoms like fever,* Correspondence: 123456mike@163.com
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reproduction in any medium, provided the orheadache, chills and not feeling well in general [2]. How-
ever, in clinical practice, symptoms caused by the common
cold vary from person to person, and cold to cold. Well
over 200 viruses are implicated in the cause of the com-
mon cold [3]. Among these pathogenic viruses, adenovi-
ruses and enteroviruses can even cause diarrhea [4-6]. It
has been reported that acute upper respiratory infection is
the most common discharge diagnosis in emergency de-
partments and the second most common diagnosis in
physician offices [7,8]. In the United States, the costs asso-
ciated with noninfluenza viral respiratory infections ared. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Standard formulation of Baoji Tablets
Pinyin name Latin name
Gouteng Ramulus uncariae cum uncis
Juhua Flos chrysanthemi
Jili Fructus tribuli
Houpo Cortex magnoliae officinalis
Cangzhu Rhizoma atractylodis
Tianhuafen Radix trichosanthis
Guanghuoxiang Herba pogostemonis
Gegen Radix puerariae
Huajuhong Exocarpium citri grandis
Baizhi Radix angelicae dahuricae
Yiyiren Semen coicis
Daoya Fructus oryzae germinatus
Bohe Herba menthae
Fuling Poria
Guangdongshenqu Massa medicata fermentata
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and direct costs [9]. Despite the high incidence and the
economic impact of the common cold, no effective etio-
logical treatment has been proven. Treatment thus mainly
comprises symptomatic relief [10]. Although various treat-
ments are used in clinical practice nowadays, few of them
are supported by any solid evidence.
Dissatisfaction with conventional treatments offered
by Western medicine has resulted in many patients seek-
ing help from complementary and alternative medicine.
Traditional Chinese medicine (TCM), a 5000-year-old
ancient system of medicine, has been used to treat a
wide range of diseases, including the common cold. The
TCM treatment for common cold is based on the differ-
entiation of symptoms and signs, such as fever, fatigue,
headache, aversion to cold, nausea and vomiting, nasal
discharge, stuffy nose, tongue proper, tongue coating
and condition of pulse. With a totally different system of
concepts and theories for etiology, TCM divides colds
into three categories: wind-heat syndrome, wind-cold
syndrome and summer-heat and dampness syndrome.
Among them, the common cold with summer-heat and
dampness syndrome (CCSDS) is most commonly seen in
midsummer and it is primarily characterized by aversion
to cold, fever, diarrhea, nausea and vomiting. According to
the basic principles of TCM, CCSDS is treated by disper-
sing summer-heat and resolving dampness, as well as im-
proving the spleen’s transportation function.
A new TCM drug, Baoji Tablets, is manufactured by
Wanglaoji Pharmaceutical Co Ltd, Guangzhou, China. It
is a new dosage form of Baoji Pills, which is an old and
famous traditional Chinese preparation in the form of
tiny round balls, 3 to 5 mm in diameter, used for treat-
ing CCSDS. This patented drug is made of active ingre-
dients from the Chinese herbs listed in Table 1, which
have all been approved by the China Food and Drug Ad-
ministration (CFDA) [11]. Preclinical pharmacologic ex-
periments showed that it can disperse summer-heat,
resolve dampness and improve the spleen’s transporta-
tion function. Furthermore, no evidence of an adverse or
toxic effect has been found in toxicological studies. The
preclinical studies were completed by Professor Rujun
Wang and her research team from the new drug deve-
lopment research center of Guangzhou Traditional
Chinese Medical University. Their studies have not yet
been published.
The objective of this well-designed randomized con-
trolled trial is to evaluate the efficacy and safety of Baoji
Tablets by comparing it with the commonly used trad-
itional preparation Baoji Pills, as well as with a placebo, for
patients with CCSDS. In this study, the investigators
hypothesize that the duration of all symptoms will be
shorter in the new tablets group. Additionally, it is expected
that the new drug will be safe for oral administration.Methods/design
Design
This study is designed as a multicenter, phase II, parallel-
group, double-blind, double-dummy, randomized and
placebo-controlled trial. The trial protocol is conducted in
accordance with the Good Clinical Practice Guidelines and
the Declaration of Helsinki (2008) [12]. This study has been
authorized by the CFDA (Approval No. 2009L00225) and
ethics approval has been obtained from local ethics com-
mittees, including the West China Hospital of Sichuan Uni-
versity Clinical Trials and Biomedical Ethics Committee,
the Ethics Committee of the Affiliated Hospital of Jiangxi
College of TCM, the Clinical Research Ethics Committee of
Fujian Institute of TCM and the Ethics Committee of
Guangxi Traditional Chinese Medical University. In
addition, the study is registered with the Chinese Clinical
Trial Registry (ChiCTR-TRC-13003197). The study is fi-
nancially supported by Wanglaoji Pharmaceutical Co Ltd,
Guangzhou, China. This funding source had no role in the
design of this study and does not have any responsibility for
analyses, interpretation of the data or the decision to sub-
mit results, other than providing test drugs. Trained re-
search nurses introduce the trial to patients, and give them
information sheets and consent forms. All patients have to
give their written informed consent prior to enrollment.
The study’s flow chart is shown in Figure 1.
Patient population and setting
A total of 288 Chinese patients, who fulfill the screening
criteria, will be enrolled at four large comprehensive
hospitals in China: 1) West China Hospital of Sichuan
University, 2) the Affiliated Hospital of Jiangxi College
of TCM, 3) Fujian Institute of TCM and 4) Ruikang
Figure 1 Study flow chart.
Table 2 Traditional Chinese medicine diagnostic criteria
Category Symptoms and signs
Primary symptoms Aversion to cold, fever, diarrhea,
nausea and vomiting
Secondary symptoms Fatigue, headache, abdominal discomfort,
poor appetite, belching
TCM signs for the tongue Reddish tongue, greasy tongue coating
TCM signs for the pulse Floating pulse, soft and slippery pulse
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versity. Each center will recruit the same number of pa-
tients. In other words, 72 patients will be recruited at
each hospital. A research assistant in each center will re-
cruit patients through advertisements in local hospitals.
Western medicine diagnostic criteria for the common cold
First, patients have to answer ‘yes’ to either of the fol-
lowing questions: A) Do you think that you have a cold?
B) Do you think you are coming down with a cold? Sec-
ond, patients have to report at least one of following
four symptoms established previously as Jackson’s cri-
teria [13]: 1) nasal discharge, 2) nasal obstruction, 3)
sneezing and/or 4) a sore throat.
Diagnostic criteria for TCM syndrome differentiation
The TCM diagnosis of summer-heat and dampness syn-
drome is based on the Guidelines for Clinical Research
of New Chinese Medicine [14]. For a patient to be diag-
nosed with summer-heat and dampness syndrome, he/
she will have at least two of each of the primary and sec-
ondary symptoms listed in Table 2, as well as the TCM
signs for the tongue and pulse.
Inclusion criteria
 Diagnosis of common cold according to Western
medicine Diagnosis of summer-heat and dampness syndrome
according to TCM
 Aged between 18 and 65 years old
 Presents within 48 hours after onset of common
cold-like symptoms
 Able to understand and sign written informed
consent
Exclusion criteria
 Patients with acute herpetic pharyngitis, acute viral
pharyngitis, acute herpetic laryngitis, acute viral
laryngitis, acute conjunctivitis or acute tonsillitis
 Patients with acute bacterial gastroenteritis
 Patients with serious primary diseases of the heart,
liver, kidney, blood system or endocrine system
 Patients with acute lower respiratory diseases,
tumors or AIDS
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times higher than the upper limit of normal
reference values, abnormal blood creatinine, positive
urine protein qualitative test, blood leukocyte count
< 3.0 × 109/L or > 10.0 × 109/L, neutrophil
percentage > 80% or stool routine test using a high
power objective finds white blood cell count > 1, pus
cells or phagocytes
 Patient’s body temperature > 38.5°C
 Patients taking any medication before the study for
relief of symptoms
 Pregnant women, hoping to become pregnant
women, lactating women
 Patients who have an allergic constitution or are
allergic to the trial medicine
 Mentally or legally disabled patients
 Patients who are participating or participated in
another drug clinical trial within the prior 3 months
Other criteria
Participants who meet any of the following criteria are
withdrawn from the study:
 Voluntarily quitting
 Misdiagnosis
 Using forbidden drugs or treatments in the course
of the trial
 Patient’s actual usage of trial drug is < 80% or > 120%
of the required dosage
 Unable to complete the scheduled follow-up
 The patient’s condition worsens during the study
and they need hospital treatment
 The patient cannot complete the study due to
adverse events or other reasons
Patients who are withdrawn are not replaced.
The whole study will be terminated or suspended early
if any of the following occur:
 Serious adverse event
 Poor curative effect is found during the study
 Significant deviation from the protocol
 Flawed protocol
 The pharmaceutical supervisory and administrative
department decides to terminate the study for any
reason
 The sponsors decide to terminate the trial due to
management or funding problems
Concomitant treatments and forbidden drugs
Use of any other Western therapy or Chinese medicine
to relieve symptoms, which may affect the analysis of
the final results, is strictly prohibited. Medications used
to control other conditions of the participants, such ashypertensive or diabetic medications, are allowed. The
dosage, duration and name of any concomitant treat-
ment or medication must be recorded carefully in the
case report form (CRF).
Test drugs
The test drugs are Baoji Tablets, dummy Baoji Tablets,
Baoji Pills and dummy Baoji Pills and they are manufac-
tured by Wanglaoji Pharmaceutical Co Ltd. Dummy
drugs are indistinguishable from the real ones. They are
almost the same in shape, size, taste and color. To make
blinding more effective, both dummy and real drugs use
the same packaging. A uniform test drug package con-
tains both tablets and pills for 3 + 1 days’ dosage. A
clearly visible tag on each package states: ‘FOR TRIAL
USE ONLY’ and other information, such as the manu-
facturer’s name, drug name, drug code, usage, dosage
and so on. All test drug packages are dispensed and
reclaimed by an independent drug administrator in each
center, who is also responsible for storing and keeping
records of test drugs.
Randomization and blinding
Stratified blocked randomization is used in this study.
Stratification is performed on enrolling centers and
block length will be decided by an independent coder,
using the software called Package for Encyclopaedia
Medical Statistics 3.1 (PEMS 3.1) to generate the
randomization sequence. Patients are assigned to the
new tablets group, old pills group or placebo control
group using a 1:1:1 ratio. The assignment for each pa-
tient is concealed in a sealed, lightproof and numbered
envelope. Each envelope is assigned to a unique coded
test drug package containing the specified medication
according to the group assignment. For example, if a pa-
tient is assigned to the new tablets group, their unique
coded test drug package will contain real Baoji Tablets
and dummy Baoji Pills. Patients are randomly enrolled
using the numbered envelopes and assigned to a treat-
ment group. A blinded clinical assistant in each center
performs the patient allocation. As the trial is double
blinded, both investigators and patients are blinded to
group assignments. The sealed envelopes are kept in
locked drawers and will only be opened if there is a
medical emergency.
Interventions
New tablets group
Patients are administered Baoji Tablets 0.9 g and dummy
Baoji Pills 3.7 g three times daily for 3 days.
Old pills group
Patients are administered dummy Baoji Tablets 0.9 g
and Baoji Pills 3.7 g three times daily for 3 days.
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Patients are administered dummy Baoji Tablets 0.9 g
and dummy Baoji Pills 3.7 g three times daily for 3 days.
All groups receive health education for the common
cold, such as the recommendation to increase rest and
fluid intake. During the study, patients are visited four
times by the investigators. The time points for the visits
are 0.5 days before baseline, at baseline, 4 days post
baseline and 11 days post baseline. The follow-up visits
last for one week after the treatment. Details of study
visits and contents can be found in Figure 2.
Outcome measurements
Primary outcomes
The primary outcome of this study will be the duration
of all symptoms, which is defined as the number of
hours from baseline to the time when the patient feelsFigure 2 Study schedule for patients.not sick at all. This can be acquired from the patient
diary, in which each patient records any changes in
symptoms.
Secondary outcomes
Secondary outcomes include duration of primary and
secondary symptoms, changes in primary and secondary
symptom scores and cumulative symptom score at day
4, as well as the evaluation of treatment efficacy. In this
trial, the symptom score system and treatment efficacy
evaluation system follow the Guidelines for Clinical Re-
search of New Chinese Medicine [14]. In the symptom
score system, the primary and secondary symptoms are
given graded scores. The cumulative symptom score is
the sum of all symptom scores. In addition, TCM signs
will also be assessed (Figure 3). The treatment efficacy
evaluation system uses the percentage of symptom score
Figure 3 Symptom scores and traditional Chinese medicine signs.
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is calculated according to the following formula:
PSSR ¼ Symptom score at day 0−Symptom score at day 4
Symptom score at day 0
 
 100%
The symptom improvement will be classified as full re-
covery (PSSR ≥ 90%), good recovery (90% > PSSR ≥ 70%),
modest recovery (70% > PSSR ≥ 30%) and no recovery
(PSSR < 30%).
Safety outcomes
Safety outcomes include results of a routine blood test,
routine urine test, routine stool test, fecal occult blood
test, liver function test, renal function test and electro-
cardiogram. These biological indicators are monitored
both before and after treatment. A urine pregnancy test
must be done before recruiting a female patient of child-
bearing age.
Data management
In our study, all data are entered electronically using Or-
acle Clinical Remote Data Capture. Original study formswill be kept on file at the participating sites for a period
of 3 years after completion of the study. At the end of
the trial, the investigators, data managers and statisti-
cians will perform a blind review and confirm the data-
base before processing the data. Only the principal
investigator will have access to the final trial data set. All
patients’ personal information is classified and is used
only in this study.Adverse event reporting
Adverse events will be recorded in detail using medical
terminology throughout the study. Severe adverse events
must be reported to both the institutional review board
and the principal investigator within 24 hours. If there is
a medical emergency, the unblinding procedures will be
initiated by the principal investigator.Sample size calculation and statistical analysis
The sample size was determined using PEMS 3.1 with
90% power and alpha = 0.05 (two-sided). The mean dur-
ation of all symptoms for a common cold was estimated
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demonstrate a reduction in the duration of all symptoms
by 2 days, which is defined as clinically relevant, the
sample size needs to be 85 cases for each group. Consid-
ering the potential loss of patients, the number of partic-
ipants recruited must be 96 per group. Therefore, a total
of 288 patients will be recruited in this trial.
The statistical analysis for this study will be performed
by an independent professional statistician using PEMS
3.1 in a separate location. An intent-to-treat analysis for
the patients, who have received treatment at least once,
will be carried out. Missing data will be adjusted using
the last observation carried forward method. The per-
protocol analysis will be restricted to participants who
strictly follow the protocol and complete the study. The
safety analysis will be conducted only for randomized
subjects who have completed at least one study visit.
Pearson’s chi-square test or Fisher’s exact test will be
performed on categorical variables, Student’s t-test on
continuous normally distributed variables and the Wil-
coxon rank sum test on non-normal variables. Due to
the multicenter design, the Cochran–Mantel–Haenszel
test stratified by clinical centers and analysis of covari-
ance adjusted for clinical center and baseline will be
used in this study. The statistical significance level will
be set at P < 0.05 and 95% confidence interval will be
calculated.
Discussion
To date, there are still no effective therapeutic options
available to treat the common cold. It seems that a vac-
cine may be a good solution. However, vaccines only
work on certain viruses. Besides, since diverse viral sero-
types cause the common cold, vaccine preparation is
very difficult. Therefore, recent studies have mainly fo-
cused on symptomatic management. TCM is widely
used in China to treat the common cold and many stud-
ies have shown that a TCM formulation might be better
in reducing symptoms than a placebo [16-19]. However,
the quality of many of these reported studies is of great
concern [20]. A number of high-quality clinical trials are
needed before any Chinese herbal preparation can be
recommended for the common cold [21]. For this rea-
son, the study protocol was designed according to the
Consolidated Standards of Reporting Trials statement
[22]. Quality controllers will pay regular visits to each
center, recheck CRFs and monitor the research data
throughout the trial. Moreover, investigators in different
centers are all required to follow the standard operating
procedures. To our knowledge, previous studies have
only focused on wind-cold syndrome and wind-heat syn-
drome. Therefore, this will be the first multicenter,
double-blind, double-dummy, randomized and placebo-
controlled trial designed to treat CCSDS in an adultpopulation from China. It will establish the basis for a
scientific and objective assessment of the efficacy and
safety of Baoji Tablets for treating CCSDS, and provide
evidence for a phase III clinical trial.
Trial status
This trial is currently recruiting participants.
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